<DOC>
	<DOCNO>NCT00216645</DOCNO>
	<brief_summary>The purpose study assess effectiveness safety pegylated liposomal doxorubicin hydrochloride injection Japanese patient Mullerian carcinoma . This clinical study multi-center , non-randomized , open-label study Japanese patient Mullerian carcinoma ( include epithelial ovarian carcinoma , primary carcinoma fallopian tube , peritoneal carcinoma ) prior history platinum-based chemotherapy . Eighty patient administer intravenously least two cycle 50 mg/m2 pegylated liposomal doxorubicin hydrochloride every 4 week investigate effectiveness safety treatment .</brief_summary>
	<brief_title>Phase II Clinical Study Pegylated Liposomal Doxorubicin Hydrochloride Injection 2nd-line Later Therapy Patients With Mullerian Carcinoma ( Epithelial Ovarian Carcinoma , Primary Carcinoma Fallopian Tube , Peritoneal Carcinoma ) Having Prior Platinum-Based Chemotherapy</brief_title>
	<detailed_description>Pegylated liposomal Doxorubicin hydrochloride intend change pharmacokinetics conventional doxorubicin blood improve safety effectiveness drug . Pegylated liposomal doxorubicin hydrochloride approve many country include US EU , become standard drug 2nd-line therapy ovarian cancer AIDS-related Kaposi 's Sarcoma . This clinical study plan assess effectiveness safety Japanese patient Müllerian carcinoma ( include epithelial ovarian carcinoma , primary carcinoma fallopian tube , peritoneal carcinoma ) , prior history receive platinum-based chemotherapy Cisplatin ( consider standard chemotherapy ovarian carcinoma ) . In study , least two cycle pegylated liposomal doxorubicin hydrochloride 50 mg/m2 intravenously administer 80 patient every 4 week . These patient include twenty 2nd-line `` platinum-sensitive '' sixty `` platinum-resistant '' 2nd-line 3rd-line patient . Pegylated liposomal doxorubicin hydrochloride 50 mg/m2 give intravenous drip infusion day 1 . After , 27-day drug-free period follow one cycle . At least two cycle give long patient meet discontinuation criterion .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Patients ovarian cancer response initial treatment relapse within 12 month eligible Patients ovarian cancer receive one two prior chemotherapy treatment eligible Patients must measurable disease , good performance status adequate major organ function Patients concomitant disease may affect conduct study evaluation pegylated liposomal doxorubicin hydrochloride Patients systemic infection Patients active second cancer besides ovarian cancer Patients pleural effusion ascites require continuous drainage time enrollment Patients pericardial fluid require drainage Patients myocardial infarction and/or angina attack within 90 day prior enrollment .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Müllerian Carcinoma</keyword>
	<keyword>Doxil</keyword>
	<keyword>Japanese Patients</keyword>
</DOC>